Xcision Medical Systems

What Xcision Medical Systems does

Xcision Medical Systems, LLC is a privately held medical technology company headquartered in Columbia, Maryland, that develops and commercializes the GammaPod stereotactic radiotherapy system, the first and only radiation therapy system purpose-built for early-stage breast cancer. The GammaPod platform consists of four integrated modules: a Multisource Cobalt-60 treatment delivery unit with 25 continuously rotating beams, a proprietary vacuum-assisted dual-cup breast immobilization system, a prone patient positioning loader, and a Monte Carlo-based treatment planning system. The technology is built on patents licensed from the University of Maryland School of Medicine and an additional 22 radiotherapy patents held by founder and CEO Dr. Cedric Yu. GammaPod received FDA 510(k) clearance in 2017 and CE Mark in 2019, and reduces conventional breast radiation treatment courses from 4-6 weeks to 1-5 fractions.

The company sells GammaPod systems as capital equipment to hospital radiation oncology departments and cancer centers, primarily through direct enterprise sales in the US and through exclusive distribution partners (Tema Sinergie in Italy, OncoMed Solutions in Switzerland/Germany/Austria) in Europe. Revenue is generated from one-time system sales plus ongoing service and support contracts, with a secondary revenue stream from licensing royalties on founder-held patents (licensed to Varian, Siemens, Elekta, and Prowess). The company operates the GammaPod Research Consortium with four founding academic medical centers to drive clinical evidence and protocol development, and has installed systems at five known clinical sites (2 US, 3 Italy) as of the latest data, with Udine reaching 100+ treatments within its first year of operation. Target customer segments are radiation oncology departments at major cancer centers and the early-stage breast cancer patients they serve, with primary use cases including stereotactic partial breast irradiation, stereotactic boost, and preoperative ablative treatment.

Name

Xcision Medical Systems

Legal name

Xcision Medical Systems, LLC

Website

https://xcision.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Xcision Medical Systems develops the GammaPod stereotactic radiotherapy system, the first radiation therapy device purpose-built for early-stage breast cancer. The company sells this capital equipment to hospital radiation oncology departments and cancer centers in the US and Europe, reducing treatment courses from weeks to 1-5 fractions.

Ownership category

akta.pro rank

Product category

Radiation Oncology Medical Devices

NAICS

Irradiation Apparatus Manufacturing (334517)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Radiation Oncology (HLAKAFAC)

akta.pro secondary industry

Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology) (EUAKAIAD)

Keywords

• Stereotactic radiotherapy
• Radiation oncology
• Breast cancer treatment
• Medical device hardware
• Cobalt-60 therapy

Headquarters

HQ city

Columbia

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. GammaPod Radiotherapy System Sales: Xcision generates revenue from the sale of GammaPod radiotherapy systems to hospitals and cancer centers. The system includes the treatment delivery unit, stereotactic localization/immobilization device, prone patient loading systems, and treatment planning software. Given the medical device nature of the product and institutional sales cycle, transactions are typically one-time capital equipment purchases with potential for service and support contracts.
2. Service and Support Contracts: The company provides customer service for user manuals, service requests, and quotations through dedicated service contacts ([email protected]). This suggests ongoing service and support revenue from installed base maintenance contracts.
3. Technology Licensing: Xcision holds patents on radiotherapy technology that are licensed to other radiotherapy companies. Six of Dr. Cedric Yu's patents are licensed to companies including Varian, Siemens, Elekta, and Prowess. Products using one patent for intensity modulated arc therapy (VMAT/Rapid Arc) have generated billions in sales, suggesting royalty income.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels15 records

Core offering

Xcision Medical Systems develops and sells the GammaPod, a first-of-its-kind stereotactic radiotherapy system purpose-built for early-stage breast cancer. The GammaPod is a multisource Cobalt-60 system that delivers highly conformal radiation in 1-5 fractions (versus 4-6 weeks of conventional therapy), combining a vacuum-assisted breast cup immobilization device, prone patient positioning, and Monte Carlo treatment planning software. The company also derives revenue from service and support contracts and licensing royalties on founder-held patents.

Product overview

Xcision Medical Systems offers a single unified product platform, the GammaPod™ Stereotactic Radiotherapy System, specifically designed for early-stage breast cancer treatment. The system comprises four integrated modules: the Treatment Delivery System (multisource Cobalt-60 unit with continuous rotation), the Stereotactic Breast Cup System (vacuum-assisted dual-cup immobilization), the Patient Treatment Loader (prone positioning system), and the Treatment Planning System (Monte Carlo-based dose calculation). The company also operates the GammaPod Consortium, a research program involving leading academic medical centers. All components work together to deliver 1-5 fraction treatments versus conventional 4-6 week regimens.

Differentiator

Problem solved

Functional benefit

Brands

• GammaPod: The first and only stereotactic radiotherapy system specifically designed for early-stage breast cancer. Uses a vacuum-assisted dual-cup breast immobilization system, prone patient positioning, and delivers treatment in 1-5 fractions (1-5 days) versus 4-6 weeks with conventional radiation therapy. GammaPod has received FDA 510(k) clearance and CE Mark in Europe.

Products and services

• GammaPod Stereotactic Radiotherapy System The first and only stereotactic radiotherapy system specifically designed for early-stage breast cancer. GammaPod delivers highly conformal, non-invasive radiation treatment in 1-5 fractions (versus 4-6 weeks conventional therapy), using a prone-positioned breast immobilization system with 25 converging Cobalt-60 beams and Monte Carlo-based adaptive treatment planning. It is sold to hospital radiation oncology departments and cancer centers.

Quantifiable outcome

• Treatment course reduced from 4-6 weeks to 5 days or fewer
• +5 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered minor and core.

• MedTech InnovatorminorOthers · 6 June 2023Xcision was selected as one of 61 startups in MedTech Innovator's 2023 Accelerator cohort. MedTech Innovator is the world's largest medical technology accelerator with over 9,000 startups reviewed and 509 companies graduated. Provides mentorship, funding opportunities, and engagement with peers and advisors through a network of 35 corporate partners and 1,000+ industry executives.
• OncoMed Solutions LLCcoreChannel Partner/ Reseller/ Distributor · 25 April 2019OncoMed Solutions LLC is the exclusive distributor of GammaPod in Switzerland, Germany, and Austria, representing Xcision's distribution network for these key European markets.
• Tema Sinergie S.p.A.coreChannel Partner/ Reseller/ Distributor · 17 April 2018Tema Sinergie S.p.A. is the exclusive distributor of GammaPod in Italy. They are a fundamental reference point for modern radiotherapy with over 30 years of direct experience. Services include consulting during design phase, user training, commissioning and go-live, technical support during and after warranty period. They organized the GammaPod launch at ASU FC Udine and represented Xcision at ESTRO 38 in Milan.
• GammaPod ConsortiumcoreStrategic or Co-development PartnerThe GammaPod Consortium is a community of pioneering institutions (University of Maryland, UT Southwestern, ASU FC Udine, IRCCS Fondazione Pascale Napoli) committed to ongoing research of clinical applications, patient outcomes, and new clinical protocols using GammaPod. Consortium members conduct clinical trials, collect outcome data, and publish clinical evidence supporting GammaPod applications.

Scale indicators6 records

Recent moves8 records

Expansion highlights7 records

Broad incumbents

• Elekta: Elekta is a global leader in radiation therapy and radiosurgery equipment (Elekta Unity, Leksell Gamma Knife) and represents a broad incumbent competing in the same radiation oncology purchasing decisions that Xcision targets.
• Carl Zeiss Meditec: Carl Zeiss Meditec manufactures the Leksell Gamma Knife, a cobalt-60-based stereotactic radiosurgery system, the closest technology analog to GammaPod's multisource Co-60 architecture and a reference point in dedicated stereotactic radiotherapy.
• Varian Medical Systems (Siemens Healthineers): Varian (now part of Siemens Healthineers) dominates the linear accelerator market with TrueBeam and Halcyon systems and licenses Dr. Yu's VMAT/Rapid Arc patent, making it the dominant incumbent Xcision competes against for hospital radiotherapy capital budgets.
• ViewRay: ViewRay developed MR-guided radiation therapy systems (MRIdian) and competes in the advanced radiotherapy equipment market with a differentiated imaging-based positioning, overlapping with Xcision's premium positioning in radiation oncology.

Emerging players

• Mevion Medical Systems: Mevion manufactures compact proton therapy systems marketed as a niche alternative to photon-based radiotherapy, analogous to Xcision's positioning of GammaPod as a dedicated, specialized alternative to general-purpose linacs.
• Sensus Healthcare: Sensus Healthcare offers the SRT-100 superficial radiation therapy system, primarily for skin cancer and keloids, and represents a niche-dedicated radiation therapy equipment vendor with a similar focused, indication-specific commercial model.
• RefleXion Medical: RefleXion developed biology-guided radiotherapy (BgRT) and X1 system, an emerging PET-guided radiotherapy platform competing in the next-generation stereotactic and adaptive radiotherapy category where Xcision also operates.
• IntraOp Medical: IntraOp provides intraoperative radiation therapy (IORT) systems such as Mobetron, an alternative radiotherapy modality often considered for early-stage breast cancer as an alternative or complement to external beam radiotherapy.

Direct peers

• Accuray: Accuray manufactures the CyberKnife and TomoTherapy stereotactic radiotherapy systems and competes directly with GammaPod in the stereotactic radiation therapy market for cancer treatment.
• Brainlab: Brainlab offers stereotactic radiosurgery and radiotherapy systems (ExacTrac, Elements) and competes in the stereotactic treatment delivery category, particularly for cranial and extracranial indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/XcisionMedical
• YouTubeyoutube.com/channel/UCr28nqkgWrM1eRGH7EGbrFQ
• Facebookfacebook.com/XcisionMedicalSystems
• LinkedInlinkedin.com/company/xcisionmedicalsystems
• Instagraminstagram.com/xcisionmedical

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xcision Medical Systems